Jiangsu Nhwa Pharmaceutical Co., LTD (SHE:002262)

Market Cap	21.35B
Revenue (ttm)	5.85B
Net Income (ttm)	1.18B
Shares Out	1.02B
EPS (ttm)	1.17
PE Ratio	17.95
Forward PE	14.39
Dividend	0.36 (1.71%)
Ex-Dividend Date	May 14, 2025

Volume	6,640,566
Average Volume	12,978,941
Open	21.06
Previous Close	21.03
Day's Range	20.98 - 21.12
52-Week Range	20.36 - 29.98
Beta	-0.20
RSI	38.06
Earnings Date	Jul 31, 2025

About SHE:002262

Jiangsu Nhwa Pharmaceutical Co., LTD engages in production, marketing, and services related to central nervous system drugs in China. It’s product portfolio includes Duloxetine Hcl, Risperidone, Ziprasidone Hcl, Etomidate Fat Emulsion, Gabapentin, Zaleplon, etc.; and Iptakalim, an anti-hypertension drug. The company’s products are used for treatment of anesthesiology, psychiatry and neurology, as well as APIs. Jiangsu Nhwa Pharmaceutical Co., LTD was founded in 1978 and is headquartered in Xuzhou, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1978
• Employees: 5,923
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002262

Financial Performance

In 2024, SHE:002262's revenue was 5.70 billion, an increase of 13.01% compared to the previous year's 5.04 billion. Earnings were 1.14 billion, an increase of 10.28%.